Does SGLT 2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Author:
Affiliation:
1. Department of Clinical Pharmacy and PharmacologyUniversity of Groningen, University Medical Center Groningen Groningen The Netherlands
2. Department of NephrologyZiekenhuisgroep Twente Almelo and Hengelo The Netherlands
Funder
No funding was received for this study.
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13057
Reference12 articles.
1. Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States
2. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment
3. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers
4. Dual renin-angiotensin system blockade at optimal doses for proteinuria
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21
2. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension;Diabetes & Metabolism Journal;2023-11-30
3. SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection;Current Molecular Pharmacology;2023-11-28
4. Nutritional Treatment as a Synergic Intervention to Pharmacological Therapy in CKD Patients;Nutrients;2023-06-12
5. Inhibition of ferroptosis of renal tubular cells with total flavones of Abelmoschus manihot alleviates diabetic tubulopathy;The Anatomical Record;2022-11-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3